Capra, MarceloMartin, ThomasMoreau, PhilippeBaker, RossPour, LudekMin, Chang-KiLeleu, XavierMohty, MohamadReinoso Segura, MartaTurgut, MehmetLeBlanc, RichardRisse, Marie-LaureMalinge, LaureSchwab, SandrineDimopoulos, Meletios2023-05-032023-05-032022-06-010390-6078http://hdl.handle.net/10668/20520Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study (clinicaltrials gov. Identifier: NCT03275285) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) versus Kd in relapsed MM. This subgroup analysis examined results from patients with RI, defined as estimated glomerular filtration rate = 3 treatment-emergent adverse events was similar between the two arms (79.1% in Isa-Kd vs. 77.8% in Kd). In summary, the addition of Isa to Kd improved clinical outcomes with a manageable safety profile in patients with RI, consistent with the benefit observed in the overall IKEMA study population.enLow-dose dexamethasonePooled analysisOpen-labelPhase-iiiLenalidomideBortezomibDialysisFailureComplicationsReversibilityresearch articleopen access10.3324/haematol.2021.2792291592-8721https://haematologica.org/article/download/haematol.2021.279229/73770836816100018